Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis

Footnotes

• Author contributions: All authors contributed to the conception and design, acquisition of data, analyses and interpretation of the data, drafted the article, revised it critically for important intellectual content, and gave final approval of the version to be published.

• Conflict of interest: M.M. Farooqi has nothing to disclose. N. Hambly reports grants from Boehringer Ingelheim and Janssen, and travel support and lecture honoraria from Boehringer Ingelheim, Janssen and Roche, outside the submitted work. C.J. Ryerson reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, consulting fees from Boehringer Ingelheim, Pliant Therapeutics and Veracyte, lecture honoraria from Hoffmann-La Roche, Boehringer Ingelheim and Cipla, and travel support from Cipla and Boehringer Ingelheim, outside the submitted work. M. Kolb reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, Pieris and Roche, consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Belerophon, Algernon and CSL Behring, lecture honoraria from Novartis, Boehringer Ingelheim and Roche, payment for expert testimony from Roche, advisory board participation with Covance and United Therapeutics, and reports a chief editor allowance from European Respiratory Society, outside the submitted work.